D3 antagonist for substance use disorder (SUD)
Ended Awarded Last action
- Contract number
- 75N95019F00088
- Awardee
-
Regents Of The University Of Minnesota UEI KABJZBBJ4B54
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,725,318
Award facts
- Opportunity
-
- N01TR19200701 Solicitation number
- Contract value 100% obligated
- $1,725,318.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Multiple Award, Fair Opportunity
- Pricing
- Time and Materials
- Place of performance
- Minneapolis, MN 55455, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$0 | |
| Other Administrative Action | -$41,669 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $93,442 | |
| Supplemental Agreement for work within scope | $329,229 | |
| Exercise an Option | $499,139 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $845,177 |
About this award
This is a federal contract award issued by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Regents of the University of Minnesota. The contract, valued at $1,725,318.18, is a Delivery Order under the NCATS "CRO Support for NCATS Medicinal Chemistry for Lead Optimization" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The work involves the development of a D3 antagonist for substance use disorder (SUD) treatment. The contract does not have a set-aside designation. The Regents of the University of Minnesota, through its Office of Sponsored Projects Administration, is the prime contractor and will be conducting the research and development work at its facilities in Minneapolis, Minnesota. This contract award leverages the university's expertise in cardiovascular research, epidemiology, and other scientific disciplines to support the NCATS mission of advancing translational sciences.
Quick answers
Who was awarded contract 75N95019F00088?
75N95019F00088 was awarded to Regents Of The University Of Minnesota by National Institute on Drug Abuse (National Institutes of Health) on September 26, 2019.
How much is contract 75N95019F00088 worth?
The government has obligated $1,725,318 on 75N95019F00088.
Which agency awarded contract 75N95019F00088?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00088, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95019F00088 an order under another contract?
Yes. 75N95019F00088 is a delivery order under 75N95019D00031, an indefinite delivery contract, on CRO Support for NCATS Medicinal Chemistry for Lead Optimization.
Was contract 75N95019F00088 competed?
The extent of competition for 75N95019F00088 was full and open competition. The government received 9 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award